Ralliant (NYSE:RAL) Price Target Raised to $82.00 at Citigroup

Ralliant (NYSE:RAL) had its target price increased by Citigroup from $81.00 to $82.00 in a research report released on Friday morning,Benzinga reports. The firm currently has a buy rating on the stock.

RAL has been the topic of several other research reports. BMO Capital Markets initiated coverage on shares of Ralliant in a research report on Monday, July 20th. They issued a “market perform” rating and a $78.00 price objective on the stock. Vertical Research downgraded shares of Ralliant from a “buy” rating to a “hold” rating and set a $65.00 target price for the company. in a research report on Wednesday, May 27th. Morgan Stanley raised their price target on shares of Ralliant from $68.00 to $85.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 23rd. Zacks Research raised shares of Ralliant from a “hold” rating to a “strong-buy” rating in a report on Tuesday, June 30th. Finally, Barclays upped their price objective on Ralliant from $52.00 to $67.00 and gave the company an “overweight” rating in a research note on Wednesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $75.70.

Ralliant Trading Down 1.8%

Shares of Ralliant stock opened at $65.78 on Friday. The firm has a market cap of $7.36 billion and a PE ratio of -6.06. Ralliant has a 1 year low of $37.27 and a 1 year high of $75.41. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.52 and a quick ratio of 1.05. The stock has a fifty day moving average price of $67.20 and a 200-day moving average price of $54.34.

Ralliant (NYSE:RAL) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.68 earnings per share for the quarter, topping analysts’ consensus estimates of $0.63 by $0.05. The company had revenue of $567.80 million for the quarter. Ralliant had a negative net margin of 56.38% and a positive return on equity of 14.97%. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. Equities research analysts anticipate that Ralliant will post 2.83 EPS for the current year.

Ralliant Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 23rd. Shareholders of record on Monday, June 8th were issued a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, June 8th. This represents a $0.20 annualized dividend and a yield of 0.3%. Ralliant’s dividend payout ratio is -1.83%.

Hedge Funds Weigh In On Ralliant

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Danske Bank A S bought a new stake in shares of Ralliant in the fourth quarter valued at approximately $25,000. V Square Quantitative Management LLC purchased a new stake in shares of Ralliant during the 4th quarter valued at approximately $26,000. Allworth Financial LP boosted its holdings in Ralliant by 134.4% in the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after buying an additional 293 shares during the period. Palisade Asset Management LLC bought a new position in Ralliant in the 3rd quarter worth approximately $26,000. Finally, BOKF NA purchased a new position in Ralliant in the 3rd quarter valued at approximately $29,000.

Key Headlines Impacting Ralliant

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Quarterly results exceeded expectations: Ralliant reported second-quarter revenue of approximately $568 million, up 13% year over year, and adjusted EPS of $0.68 versus the $0.63 consensus estimate. Adjusted net earnings were $76 million, while net earnings were $57 million. Ralliant Reports Second Quarter 2026 Results and Raises Full Year Guidance
• Positive Sentiment: Full-year and third-quarter outlooks topped consensus: Ralliant guided third-quarter EPS to $0.72-$0.78 and revenue to $570 million-$590 million, above analyst estimates of $0.68 and $556.4 million, respectively. Full-year 2026 adjusted EPS guidance was raised to $2.76-$2.90 from an analyst consensus of $2.65, with revenue expected around $2.25 billion-$2.30 billion. Ralliant forecasts 2026 revenue and productivity savings
• Positive Sentiment: Cost-reduction efforts could support future margins: Ralliant’s enterprise productivity program is targeting $50 million-$60 million in annualized run-rate savings by 2028, providing a potential boost to earnings and cash flow.
• Positive Sentiment: Analysts raised targets: Citigroup increased its target to $82 and initiated a “buy” rating, Truist raised its target to $82 while reaffirming “buy,” and RBC lifted its target to $73 while maintaining a “sector perform” rating. These targets imply meaningful upside from the recent trading level. Benzinga analyst actions
• Neutral Sentiment: Trading volatility increased: RAL experienced a temporary limit-up/limit-down trading pause during the earnings session, signaling elevated short-term volatility rather than a fundamental change in the business.
• Negative Sentiment: Valuation and execution risks remain: Despite the adjusted earnings beat, investors may continue to focus on Ralliant’s reported profitability, integration or productivity-program execution, and the gap between the stock’s recent price and analyst targets.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.